Superworth

Monopar Therapeutics revenue MNPR

Sales by quarter and over the last twelve months, from 2017.

Last 12 months, to Dec 31, 2019
$0
Latest quarter, Q4 FY19
$0
Fiscal year 2019
$0

Monopar Therapeutics' revenue was $0 over the twelve months to Dec 31, 2019.

In its latest quarter, Q4 FY19, it was $0.

Revenue over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearRevenueChange
FY2019$0n/a
FY2018$0n/a
FY2017$0n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedRevenueOn a year earlierLast 12 months
Q4 FY19$0n/a$0
Q3 FY19$0n/a$0
Q2 FY19$0n/a$0
Q1 FY19$0n/a$0
Q4 FY18$0n/a$0
Q3 FY18$0n/a$0
Q2 FY18$0n/a$0
Q1 FY18$0n/a$0
Q4 FY17$0n/a$0
Q3 FY17$0n/an/a
Q2 FY17$0n/an/a
Q1 FY17$0n/an/a

Against its peers

Companies in Drug Manufacturers - General nearest Monopar Therapeutics' size, closest first, today.

CompanyRevenue, 12 monthsGrowth
MNPRMonopar Therapeuticsn/m
ARVNArvinas$316.7M−15% a year
PBYIPuma Biotechnology$231.2M−3% a year
IRWDIronwood Pharmaceuticals$389.3M+26% a year
ZVRAZevra Therapeutics$136.1M+119% a year
CRMDCorMedix$462.2M+281% a year
COLLCollegium Pharmaceutical$808.2M+14% a year
ABUSArbutus Biopharma$181.7M
NATRNatures Sunshine Products$492M+7% a year
AMPHAmphastar Pharmaceuticals$730M+1% a year
OMEROmerosn/m
Peer median$389.3M

What the revenue tells you

Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.

Growing revenue with shrinking margins is a warning, not a win.

More on Monopar Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.